Filing Flows › Immucell (ICCC) › Q2 2026 › vs Q1 2026
Immucell (ICCC) Q2 2026 vs Q1 2026 (quarter over quarter)
Immucell's revenue fell $3.2M (-31%) from $10.4M in Q1 2026 to $7.2M in Q2 2026. Gross margin 33.9% against 45.0% (-11.1 pts).
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 33.9% | 45.0% | -11.1 pts |
| Operating margin | 26.9% | 19.0% | +7.9 pts |
| Net margin | 25.5% | 18.7% | +6.8 pts |
| Free cash flow margin | 31.8% | 32.8% | -1.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $7.2M | $10.4M | −$3.2M | -31% |
| Gross profit | $2.4M | $4.7M | −$2.2M | -48% |
| Cost of revenue | $4.7M | $5.7M | −$951K | -17% |
| Operating profit | $1.9M | $2.0M | −$34K | -2% |
| Operating expenses | $502K | $2.7M | −$2.2M | -81% |
| Pre-tax earnings | $1.9M | $2.0M | −$74K | -4% |
| Other expense, net | $54K | $15K | $39K | +258% |
| Net earnings | $1.8M | $1.9M | −$107K | -6% |
| Income tax | $46K | $13K | $33K | +267% |
| Depreciation & amortization | $471K | $531K | −$61K | -11% |
| Share-based compensation | $240K | $138K | $102K | +74% |
| Working capital & other | $474K | $962K | −$488K | -51% |
| Operating cash flow | $3.0M | $3.6M | −$554K | -16% |
| Free cash flow (OCF − capex) | $2.3M | $3.4M | −$1.1M | -33% |
| Capital expenditures | $734K | $177K | $557K | +314% |
Questions
How much did Immucell's revenue grow quarter over quarter in Q2 2026?
Immucell's revenue fell $3.2M (-31%) from $10.4M in Q1 2026 to $7.2M in Q2 2026. Gross margin 33.9% against 45.0% (-11.1 pts).